Videos

Wang and colleagues analyzed data from nearly 105,000 patients to create and test a device that can predict the efficacy of various drug combinations for hypertension.

Skarbinski explains challenges providers face when managing refractory GERD and common misconceptions about its diagnosis and treatment.

Moore describes recent progress in PBC and PSC and how this defined the field of hepatology in 2024, with lasting effects into 2025.

Cadisegliatin, a potential first-in-class oral treatment for type 1 diabetes, has been granted Breakthrough Designation by the FDA.

Stewart explains recent advances in eosinophilic gastrointestinal diseases and breaks down new ACG EoE guidelines.

Patel addresses the updated AHA/ACC hypertension guidelines, explaining important features and highlighting the potential of newer therapies.

Bhalla breaks down the newer treatments included in the recently updated AHA/ACC hypertension management guidelines.

Salvatore Viscomi, MD, warns CKDu is a growing global health crisis, driven by heat stress, toxins, and occupational risks in vulnerable populations.

Pergola breaks down findings from a phase 2 trial of OLC for managing hyperphosphatemia in patients with chronic kidney disease receiving dialysis.

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

Le discusses the implications of these new guidelines and whether the US healthcare system can manage the increasing public burden of hypertension.

Parent company Iolyx Therapeutics has announced plans to move into phase 3 trials of the investigative immunomodulator later in 2025.

In this video, the last in a 5-part series, panelists discuss their future outlook on bronchiectasis management.

In this video, the fourth in a 5-part series, panelists discuss who may benefit from brensocatib's approval.

In this video, the third in a 5-part series, panelists discuss data from the phase 3 ASPEN trial.

In this video, the second in a 5-part series, panelists discuss the recent FDA approval of brensocatib.

In this video, the first in a 5-part series, panelists discuss recent advancements in bronchiectasis management.

This episode highlights the groundbreaking approval of semaglutide for metabolic dysfunction-associated steatohepatitis, as well as GoodRx’s new Ozempic pricing.

Best discussed the landmark approval for zopapogene imadenovec for recurrent respiratory papillomatosis.

Pergola describes the shortcomings of current phosphate binders and what benefits OLC may offer for hyperphosphatemia in patients with CKD on dialysis.

Laura Ferris, MD, PhD, reflects on her unexpected path to department chair as well as the lessons of her journey as a leader in academic medicine.

This HCPLive Five episode focuses on 5 key ophthalmology updates from the ASRS2025 conference.

This August 2025 News Update spotlights Ugonabo’s career journey, her award and its story, and the growing importance of tailored dermatologic care for diverse skin tones.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from the DERM2025 meeting.

Avacincaptad pegol, pegcetacoplan, and aflibercept 8mg do not increase risk of ocular hypertension and glaucoma, despite having higher volumes.

Results from a recent trial indicated continuously decreasing risks of all forms of retinal vascular occlusion and retinal vein occlusion for 5 years after treatment.